Brief Analysis on Intravenous Immunoglobulin Treatment
Received Date: Oct 15, 2022 / Accepted Date: Nov 10, 2022 / Published Date: Nov 11, 2022
Abstract
Worldwide, the coronavirus 2 causing severe acute respiratory syndrome has infected and killed an alarming number of people. For the coronavirus illness of 2019 (COVID-19), no particular treatment has been internationally standardised; nevertheless, intravenous immunoglobulin (IVIG) has occasionally been utilised as adjuvant therapy in critically ill patients with COVID-19 pneumonia. We describe a case of a 50-year-old man who had severe COVID-19 pneumonia and had received an adjuvant 5-day IVIG regimen. We avoided using intrusive respiratory support. The patient made a full recovery and was released from the hospital without additional oxygen. Patients with severe COVID-19 pneumonia may have an improved chance of survival with a large IVIG dose. We looked at research on how IVIG use might help the early stages of the disease in the current report.
Citation: Richas Carlo NM (2022) Brief Analysis on Intravenous Immunoglobulin Treatment. J Health Care Prev, 5: 181.
Copyright: © 2022 Richas Carlo NM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 438
- [From(publication date): 0-2022 - May 20, 2024]
- Breakdown by view type
- HTML page views: 288
- PDF downloads: 150
